Published in BMC Nephrol on April 19, 2015
Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy. Adv Ther (2015) 0.90
Management of Gout and Hyperuricemia in CKD. Am J Kidney Dis (2017) 0.82
Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig (2016) 0.79
Time to target uric acid to retard CKD progression. Clin Exp Nephrol (2016) 0.77
Treatment of asymptomatic hyperuricemia in chronic kidney disease: A new target in an old enemy - A review. J Adv Res (2017) 0.75
Gout: will the "King of Diseases" be the first rheumatic disease to be cured? BMC Med (2016) 0.75
Podocyte Injury and Albuminuria in Experimental Hyperuricemic Model Rats. Oxid Med Cell Longev (2017) 0.75
Risk factors for renal impairment revealed after unilateral adrenalectomy in patients with primary aldosteronism. Medicine (Baltimore) (2016) 0.75
Diabetic nephropathy: Time to withhold development and progression - A review. J Adv Res (2017) 0.75
Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis (2016) 0.75
Stop chronic kidney disease progression: Time is approaching. World J Nephrol (2016) 0.75
The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease. Rambam Maimonides Med J (2015) 0.75
Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis. Kidney Res Clin Pract (2017) 0.75
Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial. J Adv Res (2017) 0.75
The grey zone of Hyperuricemia in chronic kidney disease. J Adv Res (2017) 0.75
Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int (2007) 7.75
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) (2012) 5.22
Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis (2006) 4.26
Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol (2010) 4.06
Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med (2009) 4.05
A role for uric acid in the progression of renal disease. J Am Soc Nephrol (2002) 3.77
Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol (2006) 3.51
Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol (2008) 3.42
Uric acid and long-term outcomes in CKD. Am J Kidney Dis (2009) 2.86
Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis (2004) 2.73
Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation (2002) 2.71
Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int (2005) 2.54
Uric acid and incident kidney disease in the community. J Am Soc Nephrol (2008) 2.44
Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res (2001) 2.35
Relationship of uric acid with progression of kidney disease. Am J Kidney Dis (2007) 2.26
The kidney in gout. Medicine (Baltimore) (1960) 2.21
Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant (2000) 2.18
High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care (2010) 2.12
Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int (2005) 2.02
Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol (2011) 1.85
Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis (2015) 1.84
Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J Am Soc Nephrol (2005) 1.76
Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis (2010) 1.65
Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant (2003) 1.51
Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant (2013) 1.47
Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant (2010) 1.45
Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron (2001) 1.32
Oxygen free radicals and contrast nephropathy. Am J Kidney Dis (1998) 1.28
Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol (2008) 1.25
Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care (2011) 1.23
Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis (2010) 1.23
Uric acid as a target of therapy in CKD. Am J Kidney Dis (2012) 1.22
A study of the natural history of diabetic kidney disease (DKD). Nephrol Dial Transplant (2011) 1.22
Screening early renal failure: cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int (1999) 1.20
New insights into uric acid effects on the progression and prognosis of chronic kidney disease. Ren Fail (2012) 1.17
Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol (2008) 1.13
Uric acid levels predict future development of chronic kidney disease. Am J Nephrol (2011) 1.10
Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res (2011) 1.10
Hyperuricaemia and accelerated reduction in renal function. Scand J Rheumatol (2010) 1.05
Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study. Nephrol Dial Transplant (2011) 0.97
Serum uric acid and chronic kidney disease: the Severance cohort study. Nephrol Dial Transplant (2011) 0.94
Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan. Nephrology (Carlton) (2011) 0.93
Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol (1999) 0.91
Cardiovascular disease in chronic kidney disease: untying the Gordian knot. Int J Clin Pract (2012) 0.90
Hyperuricemia associated with rapid renal function decline in elderly Taiwanese subjects. J Formos Med Assoc (2009) 0.90
Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nat Rev Nephrol (2011) 0.90
A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. Expert Opin Pharmacother (2009) 0.86
The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant (2001) 0.84
Uricosuric effect of losartan in patients with renal transplants. Transplantation (2001) 0.84
Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis. J Ren Nutr (2012) 0.82
Assessing kidney function in Asia. Singapore Med J (2010) 0.80
Effects of allopurinol and vitamin E on renal function in patients with cardiac coronary artery bypass grafts. Vasc Health Risk Manag (2009) 0.78